CVKD

Cadrenal Therapeutics, Inc. Common Stock

Insider Trades

NameValueActionPriceCurrent Price
Pham Quang XDirector, 10 Percent Owner, Officer: CEO And Chairman
$9.1k2.1k shares
SellJun 5, 2026
$4.42
--
Pham Quang XDirector, 10 Percent Owner, Officer: CEO And Chairman
$17k3.9k shares
SellJun 4, 2026
$4.41
--
Pham Quang XDirector, 10 Percent Owner, Officer: CEO And Chairman
$9.9k2.3k shares
SellJun 3, 2026
$4.26
--
Pham Quang XDirector, 10 Percent Owner, Officer: CEO And Chairman
$1.6k349 shares
SellJun 2, 2026
$4.46
--
Pham Quang XDirector, 10 Percent Owner, Officer: CEO And Chairman
$1.5k303 shares
SellMay 29, 2026
$5.01
--
Pham Quang XDirector, 10 Percent Owner, Officer: CEO And Chairman
$15k3k shares
SellMay 28, 2026
$4.93
--

News

globenewswire.comCadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Diseaseglobenewswire.comJun 18globenewswire.comCadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026globenewswire.comJun 15globenewswire.comCadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Eventglobenewswire.comJun 3globenewswire.comCadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026globenewswire.comMay 19globenewswire.comCadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDAglobenewswire.comMay 7